Atypical form of amyotrophic lateral sclerosis

Shoichi Sasaki, Makoto Iwata

Abstract

Objective—To investigate patients with an unusual type of muscular atrophy confined to the upper limbs (proximally dominant) and the shoulder girdle, while sparing the face and the legs until the terminal stage.

Methods—Eight patients (six men and two women) were clinically examined. The age at onset ranged from 42 to 73 years, and the clinical course varied from 28 to 81 months. There was no family history of motor neuron disease in any of these patients. Necropsy was performed in two of them.

Results—All eight patients basically showed a similar distribution of muscular weakness and atrophy. Subluxation of the shoulder joints was found in all patients. Reflexes were absent in the upper limbs in all patients, but were almost normal in the face and legs in most patients. Pathological reflexes could be elicited in only one patient. Electromyography showed typical neurogenic changes in the limbs of all patients. Cervical MRI disclosed moderate spondylotic changes in seven patients. Antiganglioside antibodies were negative in six patients tested. Abnormal trinucleotide (CAG) repeat expansion of androgen receptor gene was not recognised in five patients examined. Bulbar involvement developed in three patients during the course of the disease. At necropsy, one patient showed degeneration of the pyramidal tracts and motor cortex including Betz cells as well as loss of spinal anterior horn cells and brainstem motor neurons, which is consistent with ALS; in another patient there was neuronal loss of anterior horn cells at the spinal cord accompanied by astrogliosis, whereas the motor cortex and brainstem motor nuclei were relatively well preserved. Intracortical inclusions such as Bunina bodies, skein-like inclusions, and Lewy body-like inclusions were found in both patients.

Conclusion—These patients with their peculiar pattern of muscular atrophy seem to have ALS or a subtype of ALS.

Methods and materials

Patients

The subjects were six men and two women aged from 47 to 76 years (mean 64.4 years), with an age at onset ranging from 42 to 73 years (mean 60.0 years) and a clinical course varying from 28 to 81 months (mean 55.5 months). Three patients had bulbar signs (cases 1, 2, and 7) and two of them died of pneumonia after a clinical course of 28 (case 1) and 56 months (case 2), respectively. The other two patients (cases 3 and 4) died of respiratory failure. Patient 3 was accidentally suffocated to death possibly due to sputa. Necropsy was performed in the two patients (cases 1 and 3) within 3 hours of death.

Neuropathological studies

Tissue blocks were obtained from the brain and the spinal cord. Sections of the brain (including the motor cortex) and of the spinal cord at all levels were embedded in paraffin, cut into 6 µm sections, and stained with conventional stains such as haematoxylin-eosin (H and E) stain, a modified Bielschowsky's silver impregnation stain, and Klüver-Barrera (cresyl violet) stain.

Primary antibodies

The following antibodies were used in the present study: a polyclonal glial fibrillary acidic protein (GFAP) antibody (Dako), a rabbit polyclonal antiserum (200 kDa) to the 200 kDa protein of human neurofilament (a gift from Dr H Yamaguchi of the Department of Neurology, Gunma University) and a polyclonal antiboctin antibody (Sigma).

Immunocytochemistry

The primary antibodies were diluted with Tris-saline (50 mM Tris, pH 7.6, and 150 mM NaCl) as follows: polyclonal GFAP antibody (1:1000), polyclonal anti-200 kDa phosphorlated neurofilament antibody (1:1000), and polyclonal antiboctin antibody (1:10). Serial sections (6 µm) of the paraffin embedded motor cortex and spinal cord were alternately subjected to H and E staining and immunostaining. Sections were deparaffinised and incubated with the diluted primary antibodies overnight at 4°C. They were then visualised by the peroxidase antiperoxidase method (Dako) for GFAP, and by the avidin-biotin peroxidase complex procedure (Vectastain; Vector, Burlingame, CA, USA) for the other antibodies.
<table>
<thead>
<tr>
<th>Patient 1 (necropsy)</th>
<th>Patient 2</th>
<th>Patient 3 (necropsy)</th>
<th>Patient 4</th>
<th>Patient 5</th>
<th>Patient 6</th>
<th>Patient 7</th>
<th>Patient 8</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>M</td>
</tr>
<tr>
<td><strong>Age (y)</strong></td>
<td>72</td>
<td>76</td>
<td>76</td>
<td>48</td>
<td>48</td>
<td>67</td>
<td>67</td>
</tr>
<tr>
<td><strong>Age at onset (y)</strong></td>
<td>69</td>
<td>71</td>
<td>73</td>
<td>42</td>
<td>45</td>
<td>61</td>
<td>61</td>
</tr>
<tr>
<td><strong>Clinical course</strong></td>
<td>28 (dead)</td>
<td>56 (dead)</td>
<td>32 (dead)</td>
<td>71 (dead)</td>
<td>41 (alive)</td>
<td>81 (alive)</td>
<td>69 (alive)</td>
</tr>
<tr>
<td><strong>(months)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initial site of symptoms</strong></td>
<td>R upper limb</td>
<td>L upper limb</td>
<td>R upper limb</td>
<td>R upper limb</td>
<td>R upper limb</td>
<td>R upper limb</td>
<td>L upper limb</td>
</tr>
<tr>
<td><strong>Predominance of muscle weakness and atrophy</strong></td>
<td>SCM</td>
<td>SCM</td>
<td>SCM</td>
<td>SCM</td>
<td>SCM</td>
<td>SCM</td>
<td>SCM</td>
</tr>
<tr>
<td><strong>Reflexes</strong></td>
<td>+ (13 months after onset)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Fasciculation</strong></td>
<td>All limbs</td>
<td>All limbs and trunk</td>
<td>–</td>
<td>All limbs</td>
<td>All limbs</td>
<td>All limbs</td>
<td>Face, all limbs and trunk</td>
</tr>
<tr>
<td><strong>Complete loss of reflexes</strong></td>
<td>12 months after onset</td>
<td>17 months after onset</td>
<td>13 months after onset</td>
<td>48 months after onset</td>
<td>25 months after onset</td>
<td>37 months after onset</td>
<td>43 months after onset</td>
</tr>
<tr>
<td><strong>EMG</strong></td>
<td>Neurogenic changes in all limbs</td>
<td>Neurogenic changes in all limbs</td>
<td>Neurogenic changes in all limbs</td>
<td>Neurogenic changes in all limbs</td>
<td>Neurogenic changes in all limbs</td>
<td>Neurogenic changes in all limbs</td>
<td>Neurogenic changes in all limbs</td>
</tr>
<tr>
<td><strong>Cervical MRI</strong></td>
<td>Disc herniation (C4–6), Pincer phenomenon (C4–5)</td>
<td>Narrow canal, Disc protrusion (C3–7), Pincer phenomenon (C4–5)</td>
<td>Disc narrowing (C3–7), Slight degenerative change</td>
<td>Disc herniation (C5–6), Pincer phenomenon (C4–5, C5–6)</td>
<td>Narrow spinal canal, Disc herniation (C5–6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anti-GM1 antibody</strong></td>
<td>NE</td>
<td>NE</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>CAG repeat expansion</strong></td>
<td>NE</td>
<td>NE</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>NE</td>
</tr>
</tbody>
</table>

**Figure 1**  Clinical profile of the patients. SCM = sternocleidomastoids; NE = not examined; + = positive; − = negative.

**Electron microscopy**
The motor cortex and the anterior horns of the lumbo-sacral spinal cord were fixed in 2% glutaraldehyde with phosphate buffer (pH 7.4) at the time of necropsy. After fixation, these sections were cut into pieces about 1 mm thick, postfixed with 1% osmium tetroxide for 2 hours, dehydrated, and embedded in epoxy resin. Each block was then cut into semithin sections about 1 µm thick and stained with toluidine blue. Appropriate regions were subsequently cut into ultrathin sections and stained with uranyl acetate and lead citrate for electron microscopy.

**Results**

**CLINICAL FEATURES**
The clinical details of the patients are shown in fig 1. All eight patients basically showed a similar distribution of muscular weakness and atrophy, with atrophy being limited to the shoulder girdle (levator scapulae, pectoralis major, trapezius, deltoid, supraspinatus, infraspinatus, and interscapular muscles) and the upper limbs (fig 2). In addition, the cervical muscles including the sternocleidomastoids were affected in patients with a long course or in the terminal stage of the illness (patients 1, 2, 3, and 7). The proximal muscles of the upper limb were more severely affected than the distal muscles in all patients, with proximal muscle power being graded at only 1/5–2/5 and distal power at 3/5–4/5 in the advanced stage. The initial site of muscular weakness was the left upper limb in patients 2 and 7, and the right upper limb in the remaining 6 patients. Patients 1, 2 and 7 developed bulbar signs during the course of the disease (13, 42, and 12 months after the onset of symptoms respectively). Subluxation of the shoulder joints was seen in all patients. Fasciculation was noted both in the upper limbs and legs in six patients and three of them also showed fasciculation in the tongue. Reflexes were absent in the upper limbs of eight patients and were almost always normal in the face and legs. The reflexes in the upper limbs of eight patients were completely lost at 12, 17, 13, 48, 25, 37, 43, and 60 months after the onset of symptoms respectively (average 31.9 months). Two patients showed slightly increased tendon reflex in the legs (cases 5 and 6). Pathological reflexes (positive Babinski’s
sign) were consistently elicited in the legs of one patient (case 6). On EMG examination, reinnervation signs were demonstrated throughout the limbs in all patients, and denervation signs such as fibrillation and fasciculation were found in six patients (cases 1, 2, 4, 5, 6, and 7). Cervical MRI was performed in all patients, disclosing moderate spondylotic changes in all patients but one (patient 4) as shown in the table. Myelography was done in two patients (cases 5 and 8), showing median type disc herniation with compression of the spinal cord between C5 and C6 without narrowing of the nerve sleeves in patient 5, and defect of nerve sleeves at the left C5, C6, and C7 in patient 6. The creatine kinase (CK) concentration was slightly increased in all patients. Nerve conduction velocity (motor and sensory) was normal and there were no focal conduction blocks in all patients. Antibodies to GM1 and other glycolipids were negative in six patients (cases 3–8) who were examined. Patient 4 was ambulatory more than 5 years after the onset of muscle weakness and atrophy in the upper limbs. There was no family history of motor neuron disease, nor endocrinological impairment including gynaecomastia, in any of these patients. There was no abnormal expansion of trinucleotide (CAG) repeat of the androgen receptor gene on molecular biological study in five patients (cases 3, 4, 5, 7, and 8).

**NECROPSY FINDINGS**

**Patient 1**

Pathological examination showed marked loss of anterior horn cells at the cervical level accompanied by astrogliosis positively immunostained with anti-GFAP antibody. By contrast, anterior horn neurons persisted at the lumbosacral level, but most of the remaining neurons were degenerated. Bunina bodies were often seen in the remaining neurons. Immunohistochemically, ubiquitin positive skein-like inclusions and, less commonly, Lewy body-like inclusions were also found in anterior horn neurons. Many spheroids were seen, strongly immunostained by the polyclonal anti-200 kDa phosphorylated neurofilament antibody.
Moderate neuronal loss was noted in the hypoglossal nucleus, and the remaining neurons contained Bunina bodies. By contrast, the facial nerve nucleus was relatively well preserved, but some of the neurons contained Bunina bodies. The corticospinal tracts were degenerated at the level of the spinal cord. Electron microscopy showed Bunina bodies, skein-like inclusions, and Lewy body-like inclusions in anterior horn neurons and Betz cells.

**Patient 3**

Microscopical examination showed overall similarity with the pathological findings of patient 1. Anterior horn cells were markedly depleted at the cervical level accompanied by astrogliosis positively immunostained with anti-GFAP antibody. By contrast, anterior horn neurons at the lumbosacral level were relatively well preserved, but most of them were degenerated. Immunohistochemically, ubiquitin positive skein-like inclusions and Lewy body-like inclusions were seen in anterior horn neurons (fig 3). Many spheroids were found and immunostained by the antiphosphorylated neurofilament antibody. Betz cells and the lower motor neurons of the brainstem (trigeminal, facial, and hypoglossal motor nuclei) were relatively well preserved, and the pyramidal tracts were intact. Bunina bodies, skein-like inclusions, and Lewy body-like inclusions were found in the perikarya of anterior horn cells by electron microscopy, whereas no Betz cells had these inclusions.

**Discussion**

The clinical features such as the slowly progressive muscular weakness and atrophy, the presence of fasciculation throughout the limbs, and the diffuse neurogenic changes in the upper limbs and legs on EMG in our eight patients coincided with those of motor neuron disease. Weakness, atrophy, and fasciculations of the hands, arms, and shoulders may characterize ALS, sometimes as a dangling arm syndrome. Patients with ALS may lack upper motor neuron findings and they may have weakness largely limited to the upper limbs. However, in whatever part of the body muscular wasting begins, in most patients with ALS it spreads to the other parts of the body and sooner or later becomes generalized. More than 80% of patients with ALS with arm onset have ipsilateral or contralateral leg symptoms at 60 months after onset. On the other hand, about half of the patients with progressive spinal muscular atrophy (PSMA) have a symmetric wasting of intrinsic hand muscles, slowly advancing to the more proximal parts of the arms and less often still the proximal parts of the limbs are affected before the distal parts. Thus the pattern of muscular atrophy in our patients differed from that of typical ALS or PSMA in that severe muscle involvement was confined to the upper limbs, predominantly the proximal portion and shoulder girdle, sparing the face and the legs for a long time or until the terminal stage. Clinically, in particular, attention should be also called to the subluxation of the shoulder joints and the absence of the deep tendon reflexes in the upper limbs of these patients. Their immobile upper limbs were reminiscent of an orangutan’s hands (orangutan sign or dead arm sign, personal communication from Professor emeritus Y Toyokura, The University of Tokyo).

With regard to duration of survival, 20% of patients with ALS live longer than 5 years after the onset of symptoms, whereas the 5 year survival is 72% in patients with the onset of PSMA before the age of 50 and 40% in patients with onset after 50. Thus our patients (cases 4, 6, 7, and 8, average age at onset 57.0 years) have a long clinical course for ALS or PSMA in that they are still ambulatory without difficulty in gait more than 5 years after the onset of symptoms.

The muscle atrophy confined to the shoulder and the proximal portion of the upper limbs (forme scapulohumérale) closely similar to that of our patients was described in motor neuron disease (PSMA) more than a century ago. Six similar patients (five males and one female) with atypical muscular atrophy have also been reported in Japan in abstracts or photographs. Furukawa coined the term “suspended form” to describe this type of muscle atrophy because of its similarity to the distribution of segmental sensory impairment in syringomyelia. The age at onset in these six patients ranged from 48 to 68 years, and the clinical course was from 2 to 13 years. The authors who reported these patients considered that they were a subtype of PSMA. However, most of the patients also had cervical abnormalities such as cervical spondylosis or ossification of the posterior longitudinal ligament. Furthermore, no necropsy reports are available for these patients. Thus it remains unclear whether their progressive muscular atrophy was due to motor neuron disease, cervical spondylosis, or both diseases. Seven of our eight patients also had moderate cervical spine abnormalities, generally degenerative cervical
Atypical form of amyotrophic lateral sclerosis 585

spondylosis. It is conceivable that cervical abnormalities will cause the muscle atrophy limited to the shoulder and the proximal portion of the upper limbs, or influence the symptoms and signs of motor neuron disease in some way. Therefore, we cannot completely exclude the possibility of muscular atrophy being contributed to by a cervical spondylotic disease. However, the subsequent appearance of bulbar signs and the absence of disturbance of sensations such as numbness and hypaesthesia strongly suggest motor neuron disease rather than cervical spine abnormalities as the cause of the patients’ muscle wasting.

This type of motor neuron disease must be also distinguished from multifocal motor neuropathy, chronic segmental spinal muscular atrophy of upper extremities, and an atypical form of a motor neuron disease lacking upper motor neuron symptoms such as X linked bulbospinal muscular atrophy (Kennedy-Alter-Sung syndrome). The symmetric and marked muscular atrophy (proximal preference of muscle atrophy of the arms), the absence of antganglioside antibodies (anti-GM1 antibody) and nerve conduction block, and the neurogenic changes on EMG in all our patients are inconsistent with multifocal motor neuropathy. The age of onset, the distribution of muscle atrophy, and a clinical course with relentless progression in our patients distinctly differ from the segmental muscular atrophy of the upper extremities characterised by juvenile onset, unilateral or bilateral localisation of muscle atrophy to the intrinsic muscles of the hands and forearms, and a benign course. Also the absence of trinucleotide (CAG) repeat expansion of the androgen receptor gene is inconsistent with bulbospinal muscular atrophy.

If the El Escorial criteria for the diagnosis of ALS were applied to our patients, patient 6 might clinically fall into a slow evolving form of ALS, whereas the remaining seven patients would be categorised into the suspected form of ALS: PSPA in four patients (cases 3, 4, 5, and 7) and PSMA plus progressive bulbar palsy (PBP) in three patients (cases 1, 2, and 7). The necropsy findings of patients 1 and 3 are also compatible with those of MND: patient 1 showed involvement (degeneration) of the motor cortex including Betz cells and degeneration of the corticospinal tract as well as loss of spinal anterior horn cells and brainstem motor neurons, which is pathologically consistent with ALS despite the clinical diagnosis of the El Escorial suspected form of ALS; The neuropathological findings of patient 3 are compatible with PSMA plus PBP (case 3). Thus it is important to remember that some cases of motor neuron disease may be characterised by unusual “muscular” atrophy confined to the upper limbs with the predominance of the proximal portion and the shoulder girdle with a variable clinical course that may progress to bulbar involvement. The patients with such a peculiar pattern of muscular atrophy should perhaps be categorised as ALS or a subtype of ALS.

This work was supported in part by a grant in aid for General Scientific Research (C) from the Japanese Ministry of Education, Science, and Culture. We thank Drs S Igarashi and M Onodera (Department of Neurology, Brain Research Institute, Niigata University) for performing the DNA diagnostic test of CAG repeat expansion of androgen receptor gene and Dr S Kusumoto (Department of Neurology, Institute of Brain Research, University of Tokyo) for examining for the presence of antganglioside antibodies.

Atypical form of amyotrophic lateral sclerosis

Shoichi Sasaki and Makoto Iwata

*J Neurol Neurosurg Psychiatry* 1999 66: 581-585
doi: 10.1136/jnnp.66.5.581

Updated information and services can be found at:
http://jnnp.bmj.com/content/66/5/581

**References**

This article cites 10 articles, 2 of which you can access for free at:
http://jnnp.bmj.com/content/66/5/581#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Motor neurone disease (302)
- Neuromuscular disease (1311)
- Musculoskeletal syndromes (537)
- Spinal cord (542)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/